Navigation Links
New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer
Date:4/1/2009

DENVER, April 1 /PRNewswire-USNewswire/ -- Responding to President Obama's call for "a cure for cancer in our time," the Pharmaceutical Research and Manufacturers of America (PhRMA) delivered a new report today on medicines in the research pipeline for cancer. The report shows that America's pharmaceutical research and biotechnology companies are testing a record 861 new cancer medicines and vaccines. The medicines listed in the report are being tested in human clinical trials or are awaiting approval by the U.S. Food and Drug Administration.

Nationwide, cancer is the second leading cause of death, affecting more than 10 million Americans, according to the National Cancer Institute. This year, more than half a million Americans are expected to die of cancer -- more than 1,500 a day. In Colorado, the lifetime risk of cancer is 1 in 2 for males and 2 in 5 for females. The most commonly diagnosed cancer in the state is breast cancer, followed by prostate and lung cancer.

"We released this report in Denver because of Colorado's growing role in developing cancer medicines," said PhRMA Senior Vice President Ken Johnson, who unveiled the report at the State Capitol Building.

"Oncology is one of Colorado's core research competencies, so the President's call to cure cancer resonates powerfully in our state," said Colorado Lt. Governor Barbara O'Brien. "We are proud that the cancer medicines now in the research pipeline in Colorado are contributing substantially to the incredible progress made in the last five years by biopharmaceutical companies in developing new and more effective cancer treatments. The nation must continue its strong commitment to the cutting-edge pharmaceutical research that will enable cancer patients to live longer, healthier, and more productive lives."

"I am one of those patients who was diagnosed with cancer and was given a new treatment that brought me from the brink of death back to life," says PhRMA President and CEO Billy Tauzin. "The men and women working for America's pharmaceutical research companies are committed to developing new cancer medicines that, one day, could eradicate cancer all together."

Cancer medicines being developed include 122 for lung cancer, the leading cause of cancer death in the United States; 107 for breast cancer, which is expected to strike more than 180,000 American women this year; 70 for colorectal cancer, which is the third most common cancer in both men and women; and 103 for prostate cancer, which this year is expected to kill 28,000 American men. Additional medicines target brain cancer, kidney cancer, ovarian cancer, pancreatic cancer, skin cancer, and others.

The medicines represent many cutting-edge approaches, including a drug that delivers a synthetic version of a substance derived from scorpions directly to brain tumor cells; a number of cancer vaccines; medicines that target and kill specific cancer cells; and treatments that activate the patient's general immune system to destroy cancer.

"Researchers are making exciting progress in the search for new cures and treatments for cancer. But these efforts are wasted if the medicines we develop aren't accessible to patients who need them," said Johnson.

Help is available to patients in need through the Partnership for Prescription Assistance (PPA), a program sponsored by America's pharmaceutical research companies. To date, the PPA has helped more than 5.7 million patients nationwide, including more than 72,000 people in Colorado. Since its launch in April 2005, the PPA bus tour has visited all 50 states and more than 2,500 cities to educate people about patient assistance programs.

The "Help is Here Express" is staffed by trained specialists able to quickly help uninsured and financially struggling patients access information on more than 475 patient assistance programs, including nearly 200 programs offered by pharmaceutical companies. When the "Help is Here Express" moves on, patients can visit PPA's easy-to-use Web site (www.pparx.org) or call the toll-free phone number (1-888-4PPA-NOW).

To read Medicines in Development for Cancer 2009 on the PhRMA web site, click on the following link: http://www.phrma.org

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address: http://www.phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For information on the dangers of imported drugs, visit: http://www.buysafedrugs.info


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
2. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform
5. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
6. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
7. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
8. Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
11. New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 2017 ... Research and Markets has announced the addition of the ... their offering. The latest research Ovarian Cancer Drugs Price ... the global Ovarian Cancer market. The research answers the following ... for Ovarian Cancer and their clinical attributes? How are they positioned in ...
(Date:2/28/2017)... SOUTH SAN FRANCISCO, Calif. , Feb. 27, ... company developing proprietary therapeutics for the treatment of ... drug delivery platform, today announced that the U.S. ... initial review of the ropinirole implant Investigational New ... hold the initiation of the clinical study pending ...
(Date:2/28/2017)... SPRING, Md. and RESEARCH TRIANGLE PARK, ... Corporation (NASDAQ: UTHR ) announced today that ... United Therapeutics, will provide an overview and update on the ... Annual Health Care Conference in Boston, Massachusetts ... March 6, 2017, at 2:00 PM Eastern Time, and can ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... ... body strength, which often leads to a host of health issues, including urinary ... American Geriatrics Society discovered that good overall muscle strength in older women, ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear warfare has long plagued ... involved in the underground testing of nuclear weapons. Years later, when her co-workers began ... the Cold War Nuclear Testing,” Clayton exposes the critical decisions made by agencies involved ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the ... studies, the Center for Disease Control ( CDC ) and Infectious Diseases Society of ... Liegner, M.D. has compiled into a single volume a compelling argument that the disease ...
(Date:2/27/2017)... New Jersey (PRWEB) , ... February 27, 2017 , ... ... highest cancer rates, among all types and genders. And the need for advanced services ... by RWJ and its top-rated cancer care program, in collaboration with their non-profit partners ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC Baby Products, an ... announced it would be offering some it’s exclusive product line to the public ... and unique baby clothing/feeding products, will team up with AMAZON to distribute a ...
Breaking Medicine News(10 mins):